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Pardiovascular Risk Among
dults With Chronic Kidney Disease,
ith or Without Prior Myocardial Infarction
eattiyoat Wattanakit, MD, MPH,* Josef Coresh, MD, PHD,†
aul Muntner, PHD,‡ Jane Marsh, PHD,† Aaron R. Folsom, MD, MPH*
inneapolis, Minnesota; Baltimore, Maryland; and New Orleans, Louisiana
OBJECTIVES This study sought to determine whether chronic kidney disease (CKD) should be considered
a coronary heart disease (CHD) risk equivalent for cholesterol treatment.
BACKGROUND It is unclear whether patients with CKD have a risk of CHD events or cardiovascular disease
(CVD) mortality equivalent to patients with a prior myocardial infarction (MI).
METHODS Using data from the ARIC (Atherosclerosis Risk in Communities) study, we categorized
nondiabetic participants based on their average level of kidney function (estimated glomerular
filtration rate 60 or 30 to 59 ml/min/1.73 m2, which defines stage 3 CKD) and on prior
MI (yes or no). Rates and relative risks (RR) of CHD (MI or fatal CHD) events (n 
653) and CVD mortality (n  209) that occurred over 10 years were compared across
these populations.
RESULTS Among 12,243 middle-age participants, 271 had stage 3 CKD. After adjustment for age,
gender, race, and center, CHD incidence and CVD mortality rates per 1,000 person-years by
presence of CKD and MI were 4.1 and 1.0 in the presence of neither condition, 8.0 and 3.4
in CKD only, 18.8 and 7.0 in MI only, and 30.8 and 18.0 in CKD and MI. After further
adjustment for CVD risk factors, RR of CHD and CVD mortality were statistically
significantly lower in subjects with CKD and no prior MI (RR  0.44 [95% confidence
interval (CI) 0.28 to 0.72] for CHD and RR  0.46 [95% CI 0.24 to 0.90] for CVD
mortality) than for subjects with no CKD and a prior MI.
CONCLUSIONS Stage 3 CKD confers CHD risk that is lower and not equivalent to a prior MI in this
middle-aged, general, nondiabetic population. (J Am Coll Cardiol 2006;48:1183–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.047© 2006 by the American College of Cardiology Foundation
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ft is well established that chronic kidney disease (CKD)
ncreases the risks of cardiovascular morbidity and mortality.
hese increased risks may be explained by: 1) excess
omorbidities or cardiovascular disease (CVD) risk factors
n patients with CKD; 2) therapeutic nihilism; 3) lack of
enefit or excess toxicities from conventional CKD thera-
ies; and 4) unique pathophysiology in the CKD population
1). As a result, the National Kidney Foundation Task
orce on Cardiovascular Disease in Chronic Renal Disease
2) and other groups (3,4) have placed patients with CKD in
he highest-risk group and recommended that the thresh-
lds for risk factor intervention (e.g., drug therapy to lower
ow-density lipoprotein [LDL] cholesterol) in CKD pa-
ients be lower than in the general population. The National
holesterol Education Program Adult Treatment Panel-III
NCEP ATP-III) guidelines (5) recommend that diabetes
e considered a “risk equivalent” to coronary heart disease
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he ‡Tulane University School of Public Health and Tropical Medicine, New
rleans, Louisiana. The Atherosclerosis Risk in Communities study was supported by
ational Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-
5016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and
01-HC-55022. Dr. Wattanakit was supported by National Heart, Lung, and Blood
nstitute training grant T32-HL07779.e
Manuscript received December 14, 2005; revised manuscript received May 1, 2006,
ccepted May 16, 2006.CHD) and that patients with diabetes be treated with
ipid-lowering therapies in a similar fashion as their coun-
erparts with a prior myocardial infarction (MI). Chronic
idney disease might also be a CHD risk equivalent, but no
tudy has directly assessed whether the risk of CHD,
efined as MI or fatal CHD, and CVD mortality in patients
ith CKD is as high as in those with clinical CHD.
etermining the equivalency in risk for CKD and CHD of
uture CVD events will assist in the future modification of
reatment guidelines.
Therefore, we investigated in a nonreferral, community-
erived population whether the rates of CHD and CVD
ortality are equivalent in nondiabetic patients with: 1)
tage 3 CKD (estimated glomerular filtration rate [eGFR]
etween 30 and 59 ml/min/1.73 m2) and no history of prior
I; and 2) no CKD (eGFR 60 ml/min/1.73 m2) and a
istory of prior MI.
ETHODS
tudy population. The ARIC (Atherosclerosis Risk in
ommunities) study (6) is a prospective investigation of the
tiology and natural history of atherosclerosis. The study
ohort comprised 15,792 white and black men and women
ges 45 to 64 years at baseline in 1987 to 1989, recruited
rom four U.S. communities. The cohort underwent re-
xamination visits at roughly 3-year intervals.
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CKD as a CHD Risk Equivalent September 19, 2006:1183–9easurement of baseline risk factors. After informed
onsent, the ARIC participants underwent a standardized
edical history and examination that included interviews, a
asting venipuncture, and carotid intima-media thickness
IMT). Participants were classified as never, former, or cur-
ent smokers. Physical activity in sports was assessed using
he Baecke physical activity questionnaire, with scores
anging from 1 (low) to 5 (high), and participants were
ategorized as low (2) moderate (2 to 4), or high (4) (7).
articipants were asked to bring all current medications to
heir ARIC study visit. Medication use was recorded,
ncluding cholesterol-lowering medications, beta-blockers,
nd angiotensin-converting enzyme inhibitors. Body mass
ndex was calculated as weight in kilograms divided by the
quare of height in meters.
All participants had a standard 12-lead electrocardiogram
t baseline. A prior MI was defined as a self-reported history
f physician-diagnosed MI or a history of MI identified on
he baseline electrocardiogram, which was characterized by
he presence of a major Q-wave or a minor Q-wave with
schemic ST-T changes. Prevalent hypertension was defined
s seated diastolic blood pressure 90 mm Hg, systolic
lood pressure 140 mm Hg, or use of antihypertensive
edications within the past 2 weeks. Prevalent diabetes
ellitus was defined as a fasting serum glucose level 7.0
mol/l (126 mg/dl), nonfasting glucose level11.1 mmol/l
200 mg/l), participant report of a physician diagnosis of
iabetes, or current use of any diabetes medication.
Fasting blood samples were drawn from an antecubital
ein for measurement of total cholesterol, triglycerides,
igh-density lipoprotein cholesterol, and fibrinogen (8).
he LDL cholesterol was calculated using the Freidewald
quation. B-mode carotid ultrasound (Biosound 2000 II
A; Biosound Inc., Indianapolis, Indiana) evaluations were
ompleted on bilateral segments of the extracranial carotid
rteries using a standardized protocol (9,10). Mean far wall
MT was used for this analysis.
scertainment of the level of kidney function. To ensure
hat CKD was chronic and to decrease the effect of
ay-to-day variation in serum creatinine, we included only
Abbreviations and Acronyms
ARIC  Atherosclerosis Risk in Communities
study
CHD  coronary heart disease
CI  confidence interval
CKD  chronic kidney disease
CVD  cardiovascular disease
eGFR  estimated glomerular filtration rate
IMT  intima-media thickness
LDL  low-density lipoprotein
MI  myocardial infarction
NCEP ATP-III  National Cholesterol Education
Program Adult Treatment Panel-III
RR  relative riskarticipants who had both visit 1 and visit 2 serum creati- 2ine measured and calculated the average GFR estimate of
he 2 visits. The coefficient of variation of serum creatinine
n repeated measurement in a reliability substudy was 4.3%,
nd the reliability coefficient was 0.68 (11). Serum creati-
ine was measured using the modified kinetic Jaffe method.
he level of kidney function was ascertained by eGFR
alculated using the formula developed and validated in the
DRD (Modification of Diet in Renal Disease) study
12,13):
GFR 186.3 serum creatinine1.154 age0.203
 1.212 if black 0.742 if female.
o use this formula, serum creatinine was calibrated by
ubtraction of 0.24 (14). We assigned participants with a
hysiologically implausible high eGFR (n  3) to a maxi-
um of 200 ml/min/1.73 m2.
scertainment of incident events. The ARIC study as-
ertained CHD events and mortality from CVD after
aseline by identifying all hospitalizations and deaths. For
atients hospitalized with potential MI, trained abstractors
ecorded the presenting signs and symptoms, including
hest pain, cardiac enzymes, and related clinical informa-
ion. Out-of-hospital fatal CHD events were investigated
y an interview with one or more next of kin and a
uestionnaire completed by the patient’s physician. The
HD events were validated by a committee of physicians
sing standardized criteria (15).
A CHD event was defined as a definite or probable
ospitalized MI or definite fatal CHD. The CVD mortality
as based only on the death certificate and included any
nderlying cause of death using International Classification
f Diseases-9th Revision codes 390 to 459.
tatistical analysis. Of the 15,792 ARIC study partici-
ants, we included 13,980 participants who had serum
reatinine measured at both visit 1 and visit 2 and who did
ot have CHD events or CVD death during this interval.
f these, we excluded 192 participants with missing infor-
ation on prior MI, 85 of race other than black or white, 4
ith stage 4 CKD (eGFR of 15 to 29 ml/min/1.73 m2), and
with kidney failure (eGFR 15 ml/min/1.73 m2). Be-
ause diabetes is already considered a CHD risk equivalent,
e excluded 1,448 participants with prevalent diabetes,
eaving a total of 12,243 participants for analysis.
We followed up all participants through the year 2001. For
he CHD event analysis, follow-up time was calculated from
he visit 2 date to the time of diagnosis of a first CHD event
or those with no history of a prior MI and to the time of
iagnosis of a recurrent CHD event for those with a history
f prior MI. For participants who did not have a CHD
vent, follow-up ended on the date of last known contact or
ecember 31, 2001. For the CVD mortality analysis,
ollow-up time was calculated from the visit 2 date to the
ate of death, date of last known contact, or December 31,
001.
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September 19, 2006:1183–9 CKD as a CHD Risk EquivalentWe categorized participants based on whether they had
tage 3 CKD (hereafter referred to as CKD) or not and a
aseline history of a prior MI or not. The categories were as
ollows: 1) no CKD and no prior MI as group 1; 2) no CKD
nd prior MI as group 2; 3) CKD and no prior MI as group
; and 4) CKD and prior MI as group 4. These categories
ere coded with group 2 serving as the reference group
or all analyses. Next, we compared participant characteris-
ics across the four categories with differences assessed using
nalysis of variance, adjusted for age, gender, race, and
RIC study field center. Kaplan-Meier curves were created
o compare the probability of CHD events and CVD
ortality for each category. Age-, gender-, race-, and field
enter-adjusted incidence rates per 1,000 person-years for
he two outcomes (CHD events and CVD mortality) were
alculated for each CKD and prior MI category using
oisson regression. Proportional hazards regression was
sed to calculate relative risks (RR) and 95% confidence
ntervals (CI) of CHD events and CVD mortality for each
ategory, adjusting for age, gender, race, and ARIC study
eld center and then additionally for cigarette smoking
current, former, never), systolic blood pressure, physical
ctivity, LDL and high-density lipoprotein cholesterol,
brinogen, carotid IMT, and use of cholesterol medications
nd antihypertensive medications. Analyses were conducted
sing SAS version 8.2 (SAS Institute, Cary, North Carolina).
ESULTS
mong the 12,243 participants, the mean visit 1 eGFR was
2.5 (SD  19.5) ml/min/1.73 m2 and visit 2 eGFR was
able 1. Baseline Characteristics of Men and Women Across Ch
lomerular Filtration Rate (eGFR) and Categories of Prior Histo
Baseline
No CKD,
No Prior MI
(Group 1)
No C
Prior
(Grou
o. of subjects 11,606 366
ale, % 43.5 77
ge, yrs 54 57
hite participants, % 77.7 82
edian eGFR, ml/min/1.73 m2 88 86
revalence,* (%)
Hypertension 29.1 43
Current smoking 24.7 28
ean levels*
Physical activity score 2.0 2
Body mass index, kg/m2 27.1 27
Systolic blood pressure, mm Hg 120 118
Total cholesterol, mg/dl 214 223
LDL cholesterol, mg/dl 137 146
HDL cholesterol, mg/dl 52.9 48
Fibrinogen, mg/dl 297 316
Carotid intima-media thickness, mm 0.71 0
edication use, %
Use of beta-blockers at baseline 8.9 39
Use of ACE inhibitors at baseline 2.8 5
Use of cholesterol medication 2.3 7Adjusted for age, sex, race, and ARIC field center.
ACE  angiotensin-converting enzyme; HDL  high-density lipoprotein; LDL  low6.6 (SD  18.1) ml/min/1.73 m2. The average eGFR of
he 2 visits was 89.6 (SD  17.2) ml/min/1.73 m2. The
ean age was 54 years. Among 271 participants with CKD,
20 (81.2%) had eGFR between 50 and 60 ml/min/1.73 m2,
1 (15.1%) had eGFR between 40 and 49 ml/min/1.73 m2,
nd 10 (3.7%) had eGFR between 30 and 39 ml/min/
.73 m2. The mean eGFR was 54.1 (SD  5.8) ml/min/
.73 m2. As Table 1 shows, at baseline patients in group 1
ad the most favorable CVD risk factor profile, and those in
roup 4 had the worst CVD risk factor profile. Compared
ith patients in group 2, patients in group 3 were more
ikely to be female, white, and older, and had a lower
revalence of current smoking as well as lower mean values
f LDL cholesterol and carotid IMT.
During a mean follow-up of 10 years (123,213 person-
ears), we identified 653 CHD events and 209 deaths from
VD. The Kaplan-Meier analysis showed a greater proba-
ility of CHD (p  0.0001) and CVD mortality (p 
.001) for patients in group 2 than for those in group 3
Figs. 1 and 2).
As Table 2 shows, after adjustment for age, gender, race,
nd ARIC study field center, the CHD event rate for
atients in group 1 was 4.1 per 1,000 person-years, which
as about 50% lower than that of those in group 3 (8.0 per
,000 person-years). The CHD event rate was 18.8 per
,000 person-years for those in group 2 and 30.8 for those
n group 4. Compared with patients in group 2, those in
roup 1 had a lower multivariable adjusted RR of CHD
RR  0.29, 95% CI 0.23 to 0.37). The analogous multi-
ariable adjusted RR for patients in group 3, compared with
Kidney Disease (CKD) Categories Based on Estimated
f Myocardial Infarction (MI): the ARIC Study
Stage 3 CKD,
No Prior MI
(Group 3)
Stage 3 CKD,
Prior MI
(Group 4)
p Value for Contrast
Comparing Group 2
vs. Group 3
250 21
37.2 71.4 0.0001
58 60 0.0001
89.6 81.0 0.01
56 55 0.0001
50.2 68.9 0.054
17.8 20.7 0.004
2.0 2.1 0.74
28.2 29.7 0.13
123 121 0.0001
217 213 0.08
140 137 0.04
49.3 43.3 0.57
313 299 0.58
0.73 0.82 0.0001
23.7 50.0 0.0001
9.7 30.0 0.07
3.9 19.1 0.06ronic
ry o
KD,
MI
p 2)
.9
.2
.2
.1
.0
.6
.6
.78
.8
.6
.7-density lipoprotein.
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CKD as a CHD Risk Equivalent September 19, 2006:1183–9atients in group 2, was 0.44 (95% CI 0.28 to 0.72).
lthough not statistically significant, patients in group 4
ad the highest risk of CHD, with a multivariable adjusted
R of 1.64 (95% CI 0.79 to 3.42) compared with the
eference group.
The lowest CVD mortality rate was found in those in
roup 1 (1.0 per 1,000 person-years), and the highest rate
as found in those in group 4 (18.0 per 1,000 person-years).
atients in group 3 had a CVD mortality rate about half
hat of those in group 2 (3.4 vs. 7.0 per 1,000 person years).
ompared with patients in group 2, the multivariable-
djusted RR of CVD mortality in patients in group 1 was
.18 (95% CI 0.12 to 0.26) and was 0.46 (95% CI 0.24 to
.90) in patients in group 3. Patients in group 4 again had
he highest RR of CVD mortality, with an almost two-fold
reater risk than the reference group (RR  1.87, 95% CI
.76 to 4.60).
When the multivariable analyses were repeated using
ime-dependent covariates for use of cholesterol and anti-
igure 1. Kaplan-Meier curves for a coronary heart disease (CHD) event
therosclerosis Risk in Communities (ARIC) study, 1990–2001.igure 2. Kaplan-Meier curves for cardiovascular disease (CVD) mortality b
therosclerosis Risk in Communities (ARIC) study, 1990–2001.ypertensive medications, the adjusted RRs of CHD and
VD mortality were comparable with the results using
aseline (i.e., fixed) covariates (data not shown).
ISCUSSION
o determine whether CKD confers the same excess risk as
linical CHD, we characterized the rates of CHD events
nd CVD mortality in nondiabetic patients with stage 3
KD and in patients without CKD, with or without prior
I. Among patients with a prior MI in this study, those
ith stage 3 CKD had increased rates of CHD events and
VD mortality compared with those with no CKD. Our
ndings support previous reports showing that CKD in-
reases the risk of CHD events and mortality in high-risk
ubjects with known vascular disease or diabetes (16),
aseline hypertension (17), or baseline CHD (18–20). The
ajor new finding of this study is that in a community-
erived sample, nondiabetic patients with stage 3 CKD and
hronic kidney disease (CKD) and myocardial infarction (MI) status: they chronic kidney disease (CKD) and myocardial infarction (MI): the
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September 19, 2006:1183–9 CKD as a CHD Risk Equivalento prior MI had a CHD event rate 60% lower and a CVD
ortality rate nearly 50% lower than did those with no
KD and a prior MI.
Whether CKD is a “CHD risk equivalent,” using NCEP
TP-III terminology (5), is not well established. Data have
onsistently shown that CKD patients have a higher risk of
nd poorer survival from CVD events than does the general
opulation (21). In response to these findings, numerous
orking groups have recommended that CKD should be
lassified as a CHD risk equivalent (2–4), justifying the
niform consideration of pharmacologic cholesterol-
owering therapy (e.g., with statins) at lower LDL choles-
erol levels. On the other hand, recent NCEP ATP-III (5)
nd European (22) guidelines have not recognized CKD as
CHD risk equivalent. In the current study, middle-age,
ondiabetic patients with stage 3 CKD and no prior MI did
ot have a rate of CHD events as high as those with no
KD and a prior MI. Nondiabetic patients with stage 3
KD and no prior MI had a 10-year rate of CHD events of
.0%, whereas those with no CKD and a prior MI had
8.8% risk of having a CHD (i.e., 18.8 of 100 subjects will
evelop an incident CHD event within 10 years). These
ata suggest that stage 3 CKD is not a CHD risk equiva-
ent. Because the 10-year CHD event rate in middle-age,
ondiabetic patients with stage 3 CKD was 10% or less (5)
Table 2), aggressive statin therapy of LDL cholesterol in
hese patients is likely to be less cost effective than in those
ith a history of prior MI. Hence, this study suggests that
t may be more appropriate or cost-effective to tailor lipid
anagement for patients with stage 3 CKD based on each
ndividual patient’s global CHD risk assessment (5).
Decreased kidney function is increasingly recognized as a
isk factor for CVD mortality and all-cause mortality in the
eneral population (23–26). For example, one study, which
ooled data from four large community-based studies,
howed that patients with stage 3 to 4 CKD had RRs of
.36 (95% CI 1.21 to 1.53) for all-cause mortality and 1.19
95% CI 1.07 to 1.32) for a composite outcome (MI, fatal
able 2. Relative Risks of Coronary Heart Disease and Mortality
isease (CKD) and Without CKD, With or Without History of
No CKD,
No Prior MI
(Group 1)
o. of subjects 11,606
atal coronary heart disease or MI (n  653) 529
Event rate per 1,000 person-years* 4.1
RR (95% CI)* 0.21 (0.17–0.27)
Multivariable RR (95% CI)† 0.29 (0.23–0.37)
ardiovascular disease mortality (n  209) 146
Death rate per 1,000 person-years* 1.0
RR (95% CI)* 0.14 (0.10–0.20)
Multivariable RR (95% CI)† 0.18 (0.12–0.26)
Adjusted for age, gender, race, and ARIC field center. †Adjusted for age, gender, race
ipoprotein and high-density lipoprotein cholesterol, fibrinogen, carotid intima-media
nd angiotensin-converting enzyme inhibitors) use. The p values of all covariates in
CI  confidence interval; RR  relative risk.HD, stroke, and all-cause mortality) compared with those eith eGFR 60 ml/min/1.73 m2 (26). To our knowledge,
ur study is the first to report that the rate of CVD mortality
n nondiabetic patients with stage 3 CKD and no prior MI
s lower than in patients with no CKD and a prior MI.
Also considered for statin therapy might be those with
tage 4 CKD. Such patients were rare in our population-
ased sample (n  4), but a recent large study by Go et al.
27) reported age-standardized CVD event rates of 37, 113,
18, and 366 per 1,000 person-years for eGFR levels of 45
o 59, 30 to 44, 15 to 29, and 15 ml/min/1.73 m2,
espectively. In the same study, the age-standardized death
ates were 10.8, 48, 114, and 141 per 1,000 person-years for
GFR levels of 45 to 59, 30 to 44, 15 to 29, and 15
l/min/1.73 m2, respectively. Although approximately 20%
f patients with CKD in that study already had CHD (27),
he high rates of CVD and mortality at an eGFR 30
l/min/1.73 m2 suggest stage 4 CKD (eGFR of 15 to 29
l/min/1.73 m2), and kidney failure might warrant CHD
isk equivalent status.
Many previous studies that evaluated the association of
he level of kidney function with CVD morbidity and mortal-
ty have focused on selected high-risk groups (19,28–30). In
his study, we included middle-age, nondiabetic men and
omen from 4 U.S. community-based samples and aver-
ged eGFR from 2 ARIC visits to define stage 3 CKD. The
istribution of eGFR observed in this study should be
epresentative of that of patients with stage 3 CKD, and our
esults, therefore, are generalizable to the population 45 to
4 years of age with stage 3 CKD. We nevertheless
cknowledge a series of limitations. First, there are potential
ources of misclassification. The eGFR from serum creati-
ine using the MDRD formula may not be as accurate as a
irect measurement from iothalamate or creatinine clear-
nce using a 24-h urine collection. These measurements,
owever, are not feasible in a large epidemiologic study and
re generally not performed in clinical practice. Our meth-
ds conform to current recommendations for estimation of
idney function using creatinine-based equations. If better
m Cardiovascular Disease in Persons With Chronic Kidney
cardial Infarction (MI): the ARIC Study, 1987–2001
No CKD,
Prior MI
(Group 2)
Stage 3 CKD,
No Prior MI
(Group 3)
Stage 3 CKD,
Prior MI
(Group 4)
366 250 21
94 22 8
18.8 8.0 30.8
1.0 ref. 0.39 (0.24–0.62) 1.68 (0.82–3.46)
1.0 ref. 0.44 (0.28–0.72) 1.64 (0.79–3.42)
45 12 6
7.0 3.4 18.0
1.0 ref. 0.46 (0.24–0.87) 2.42 (1.03–5.69)
1.0 ref. 0.46 (0.24–0.90) 1.87 (0.76–4.60)
field center, cigarette smoking, systolic blood pressure, physical activity, low-density
ess, cholesterol medication and antihypertensive medication (including beta-blockers
justed model were 0.05, except for center and race.Fro
Myo
, ARIC
thicknstimation of kidney function is possible, the consequent
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CKD as a CHD Risk Equivalent September 19, 2006:1183–9HD and CVD risk associated with CKD may be higher,
s seen in recent articles reporting using cystatin C as an
stimate of decreased kidney function (31,32). Having a
rior MI at baseline was not validated, but relied on a
elf-reported history and electrocardiogram, creating an-
ther potential source of misclassification. Nevertheless, the
alidity of self-report assessment was confirmed by medical
ecords in 75.5% of men and 60.6% of women in the
ardiovascular Health Study (33). Data on markers of
idney damage, such as microalbuminuria, were not avail-
ble in the full ARIC study cohort. As such, patients with
GFR 60 ml/min/1.73 m2 and microalbuminuria (i.e.,
tage 1 and 2 CKD) were included into the “no CKD”
rouping. This misclassification is likely to have biased the
bserved association away from the null. Second, the defi-
ition of CKD included a broad range of GFR. Our sample
ize did not allow us to separately estimate the rate of CHD
vents in relation to stage 4 CKD and no prior MI. Third,
ther nontraditional CVD risk factors such as homocysteine
nd C-reactive protein were not measured in the ARIC
tudy, and these risk factors have recently been identified to
lay a role in the development of CVD mortality in patients
ith CKD (34,35). Fourth, the ARIC study reported serum
reatinine values to ARIC study participants and their
hysicians. It is possible that awareness of serum creatinine
ight have changed the treatment plan for some partici-
ants with CKD. Lastly, the ARIC study did not have
nformation at baseline on time since prior MI or onset of
KD, or on severity of prior MI. Differences in these
mong various groups compared could have impacted the
vent rate and RR estimates.
Although CKD was associated with increased rates of
HD and CVD mortality, nondiabetic participants in the
RIC study with stage 3 CKD did not have the same rate
f CHD and CVD mortality as their counterparts with a
istory of MI in this population of middle-age adults. As
uch, CKD does not seem to carry the same burden of
HD risk and CVD mortality as having a prior MI.
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